Angelman Syndrome — a severe neurodevelopmental condition caused by four different genetic mechanisms, requiring molecular subtype identification now that gene therapy trials make precise genotyping directly therapeutic.
Whole genome sequencing characterizes all four Angelman syndrome molecular mechanisms simultaneously — UBE3A variants, 15q11-q13 deletions, paternal uniparental disomy, and imprinting center defects — in the era of emerging precision therapies.
Angelman Syndrome
Angelman syndrome (AS) is a severe neurodevelopmental disorder characterized by intellectual disability, absence of speech, seizures, ataxia, microcephaly, characteristic facial features, and a notably happy, sociable demeanor with frequent smiling and laughter. It affects approximately 1 in 12,000-20,000 individuals. The condition is caused by loss of function of the maternal copy of the UBE3A gene on chromosome 15q11-q13, which encodes an E3 ubiquitin ligase. UBE3A is subject to genomic imprinting in neurons — only the maternally inherited copy is expressed, while the paternal copy is silenced by a non-coding antisense transcript (UBE3A-ATS). Loss of the maternal UBE3A copy therefore eliminates UBE3A protein expression in neurons.
Angelman syndrome arises through four distinct genetic mechanisms, each with different recurrence risks and treatment implications: (1) Large maternal 15q11-q13 deletions — the most common cause, accounting for approximately 70-75% of cases, detectable by chromosomal microarray or copy number variant analysis; (2) Paternal uniparental disomy (UPD) of chromosome 15 — two paternal copies and no maternal copy, accounting for approximately 7% of cases, detectable by methylation analysis; (3) Imprinting center defects — microdeletions or epigenetic errors affecting the imprinting control region, accounting for approximately 3% of cases; (4) UBE3A sequence variants — pathogenic intragenic variants in UBE3A accounting for approximately 10-15% of cases, detectable by gene sequencing. Approximately 10% of clinically diagnosed AS cases remain molecularly unresolved.
The treatment landscape for Angelman syndrome has been transformed by emerging antisense oligonucleotide (ASO) therapies designed to silence the paternal UBE3A-ATS transcript, unblocking paternal UBE3A expression and restoring neuronal UBE3A protein. Multiple clinical trials (including GTX-102 and others) are underway or have reported preliminary results. These therapies work by activating the silenced paternal UBE3A allele and therefore require the paternal UBE3A copy to be intact — they are relevant only for patients in whom the loss of maternal function is not accompanied by loss of the paternal allele (i.e., deletions, UPD, and imprinting defects, not UBE3A sequence variants where the paternal copy is still silenced but intact). Knowing the molecular mechanism is essential for trial eligibility.
The four Angelman syndrome mechanisms have different recurrence risks: deletions and UBE3A variants can be familial; UPD has low recurrence; imprinting center microdeletions can recur at up to 50%. Precise molecular classification determines genetic counseling.
Diagnosing Angelman syndrome requires multiple tests — methylation analysis, chromosomal microarray, and UBE3A sequencing. Whole genome sequencing addresses all four molecular mechanisms in a single test, including copy number variants, imprinting defects, and UBE3A sequence variants.
Sequential multi-test diagnostic odysseys delay treatment in a time-sensitive condition
Current standard diagnostic practice for suspected Angelman syndrome involves a sequential testing cascade: methylation-specific PCR or MLPA first (detects deletions, UPD, and imprinting defects), followed by chromosomal microarray if methylation is abnormal, followed by UBE3A sequencing if methylation study is normal. Each step requires additional time, additional samples, and additional cost. The average time to Angelman syndrome diagnosis is approximately 3 years from symptom onset — a delay during which families live without answers and critically, before emerging therapies could potentially be initiated. Whole genome sequencing evaluates all four molecular mechanisms simultaneously.
ASO therapy eligibility requires knowing which mechanism caused the disease
GTX-102 and similar antisense oligonucleotides targeting UBE3A-ATS work by unblocking expression of the paternal UBE3A allele. For this to restore neuronal UBE3A function, the paternal UBE3A allele must be present and intact. Patients with large 15q11-q13 deletions — who lack the paternal UBE3A allele entirely — are not candidates for this mechanism-based therapy. Patients with UBE3A sequence variants have an intact paternal UBE3A allele that could potentially be unblocked. Establishing the precise molecular mechanism — deletion vs. UPD vs. imprinting defect vs. UBE3A variant — is therefore prerequisite for clinical trial enrollment and future approved therapy selection.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Angelman Syndrome and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
